167 related articles for article (PubMed ID: 22396745)
21. Antiviral effect of raltegravir on HTLV-1 carriers.
Treviño A; Parra P; Bar-Magen T; Garrido C; de Mendoza C; Soriano V
J Antimicrob Chemother; 2012 Jan; 67(1):218-21. PubMed ID: 21965433
[TBL] [Abstract][Full Text] [Related]
22. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
[TBL] [Abstract][Full Text] [Related]
23. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
24. Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.
Westin MR; Biscione F; Ribeiro KM; Greco DB; Tupinambás U
AIDS Res Hum Retroviruses; 2014 Feb; 30(2):113-7. PubMed ID: 23875625
[TBL] [Abstract][Full Text] [Related]
25. Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich R; Allavena C; Peytavin G; Soulie C; Tubiana R; Weiss L; Montoya Ferrer A; Duvivier C; Bouchaud O; Bottero J; Durand A; Lê MP; Marcelin AG; Dudoit Y; Assoumou L; Katlama C;
J Antimicrob Chemother; 2021 Jan; 76(2):477-481. PubMed ID: 33099638
[TBL] [Abstract][Full Text] [Related]
26. Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients.
Bon I; Calza L; Musumeci G; Longo S; Bertoldi A; D'Urbano V; Gibellini D; Magistrelli E; Viale PL; Re MC
Curr HIV Res; 2017; 15(6):448-455. PubMed ID: 29210661
[TBL] [Abstract][Full Text] [Related]
27. [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
Llibre JM; Martínez-Picado J
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():17-22. PubMed ID: 19572421
[TBL] [Abstract][Full Text] [Related]
28. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.
Murray JM; McBride K; Boesecke C; Bailey M; Amin J; Suzuki K; Baker D; Zaunders JJ; Emery S; Cooper DA; Koelsch KK; Kelleher AD;
AIDS; 2012 Mar; 26(5):543-50. PubMed ID: 22410637
[TBL] [Abstract][Full Text] [Related]
29. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
[TBL] [Abstract][Full Text] [Related]
32. Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.
Bona R; Baroncelli S; D'Ettorre G; Andreotti M; Ceccarelli G; Filati P; Leone P; Blasi M; Michelini Z; Galluzzo CM; Mallano A; Vullo V; Cara A
AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1365-9. PubMed ID: 23802629
[TBL] [Abstract][Full Text] [Related]
33. Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.
Baroncelli S; Pirillo MF; Galluzzo CM; Antoni AD; Ladisa N; Francisci D; d'Ettorre G; Segala D; Vivarelli A; Sozio F; Cirioni O; Weimer LE; Fragola V; Parruti G; Floridia M
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):71-7. PubMed ID: 25092266
[TBL] [Abstract][Full Text] [Related]
34. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
Wittkop L; Breilh D; Da Silva D; Duffau P; Mercié P; Raymond I; Anies G; Fleury H; Saux MC; Dabis F; Fagard C; Thiébaut R; Masquelier B; Pellegrin I;
J Antimicrob Chemother; 2009 Jun; 63(6):1251-5. PubMed ID: 19336453
[TBL] [Abstract][Full Text] [Related]
35. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
Gallien S; Delaugerre C; Charreau I; Braun J; Boulet T; Barrail-Tran A; de Castro N; Molina JM; Kuritzkes DR
AIDS; 2011 Mar; 25(5):665-9. PubMed ID: 21326075
[TBL] [Abstract][Full Text] [Related]
36. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
37. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
38. Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
Buzón MJ; Codoñer FM; Frost SD; Pou C; Puertas MC; Massanella M; Dalmau J; Llibre JM; Stevenson M; Blanco J; Clotet B; Paredes R; Martinez-Picado J
PLoS Pathog; 2011 Oct; 7(10):e1002314. PubMed ID: 22046128
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
[TBL] [Abstract][Full Text] [Related]
40. Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
Rozera G; Fabbri G; Lorenzini P; Mastrorosa I; Timelli L; Zaccarelli M; Amendola A; Vergori A; Plazzi MM; Cicalini S; Antinori A; Capobianchi MR; Abbate I; Ammassari A
PLoS One; 2017; 12(10):e0187095. PubMed ID: 29077766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
